Back to results
US 2015/0030589 A1Published application
Abeta antibody formulation
AssigneeHoffmann-La Roche Inc.
InventorsPierre Goldbach, Hanns-Christian Mahler, Robert Mueller
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical formulation comprising about 50 mg/ml-200 mg/ml of an Abeta antibody, about 0.01%-0.1% poloxamer, about 5 mM-50 mM of a buffer, about 100 mM-300 mM of a stabilizer at a pH of about 4.5-7.0.
Claims59
A stable liquid pharmaceutical antibody formulation comprising:
- about 50 mg/ml-200 mg/ml of an Abeta antibody,
- about 0.01%-0.1% of a poloxamer, preferably poloxamer 188,
- about 5 mM-50 mM of a buffer,
- about 100 mM-300 mM of a stabilizer,
- wherein the formulation has a pH of about 4.5-7.0
2 more elements
3-18. (canceled)
The pharmaceutical formulation according to claim 3, wherein the buffer is a sodium acetate buffer or a Histidine buffer.
Dependencies are inferred from the claim text.